NPS PHARMACEUTICALS INC
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | |
|---|---|---|---|---|---|---|
| Revenue | $44.0M | $25.4M | $130.6M | $101.6M | $89.4M | $84.1M |
| Operating income | −$2.9M | −$4.5M | −$1.1M | $545,000 | $9.6M | $27.7M |
| Net income | −$8.7M | −$13.5M | −$18.7M | −$36.3M | −$31.4M | −$17.9M |
| Total assets | $289.6M | $292.2M | $151.1M | $214.0M | $228.9M | — |
| Total liabilities | $155.8M | $187.3M | $205.8M | $260.1M | $384.2M | — |
| Equity | $133.8M | $104.9M | −$54.6M | −$46.1M | −$155.3M | −$222.8M |
| EPS (diluted) | $-0.06 | $-0.09 | $-0.22 | $-0.45 | — | — |
| Shares out. | 102.8M | 86.9M | 86.1M | 86.1M | 67.0M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2014- Operating margin
- −6.7%
- Net margin
- −19.8%
- Return on equity
- −6.5%
- Return on assets
- −3.0%
- Return on capital (ROCE)
- −1.3%
- Liabilities / assets
- 53.8%
- Debt / equity
- 1.16×
- Book value / share
- $1.30
- Revenue growth (YoY)
- 73.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2014- Altman Z″ (distress)
- -6.23distress
- Accruals / assets
- 2.8%clean
- Beneish M-Score
- -1.80normal
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 3 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 12, 2008
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Garceau RogerOfficer — SVP & CMO | Feb 21, 2015 | U | 43,349 | $46.00 |
| Firuta Paul EOfficer — President, US Comm Operations | Feb 21, 2015 | U | 1,114 | $46.00 |
| Rogus Joseph JOfficer — SVP, GTO & Supply Chain Mngmt | Feb 21, 2015 | U | 21,663 | $46.00 |
| Nader FrancoisOfficer — President, CEO and Director | Feb 21, 2015 | U | 276,955 | $46.00 |
| Bonney Michael WDirector | Feb 21, 2015 | U | 13,900 | $46.00 |
| Tombros Peter GDirector | Feb 21, 2015 | U | 57,625 | $46.00 |
| Graf Susan EOfficer — VP,Corp Development & Strategy | Feb 21, 2015 | U | 4,761 | $46.00 |
| Broom Colin MdDirector | Feb 21, 2015 | U | 24,313 | $46.00 |
| Gemayel GeorgesDirector | Feb 21, 2015 | U | 9,000 | $46.00 |
| Selisker Rachel RDirector | Feb 21, 2015 | U | 7,400 | $46.00 |
| Groninger James GDirector | Feb 21, 2015 | U | 9,188 | $46.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsFeb 23, 2015
- Entered a material agreement · Director / officer change · Amended charter or bylaws · Other material eventJan 12, 2015
- Results of operationsNov 10, 2014
- Director / officer changeNov 4, 2014
- Other material eventSep 12, 2014
- Results of operationsAug 6, 2014
- Other material eventJun 10, 2014
- Regulation FD disclosureJun 2, 2014
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.